Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company announced positive results from pivotal Phase 3 clinical trials of setmelanotide, its melanocortin-4 receptor (MC4R) agonist, in people living with pro-opiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity. Rhythm is also evaluating setmelanotide in a pivotal Phase 3 trial in people living with Bardet-Biedl and Alstrom syndromes. Rhythm is leveraging the Rhythm Engine – comprised of its Phase 2 basket study, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program – to improve the understanding, diagnosis and potentially the treatment of rare genetic disorders of obesity.
For healthcare professionals, visit www.UNcommonObesity.com for more information.
For patients and caregivers, visit www.LEADforRareObesity.com for more information. The company is based in Boston, MA.